Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trialNathan Fowler, Catherine Thiéblemont, Jason Butler et al.|Nature Medicine|2021Cited by 523
Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in HumansMichael C. Jensen, Stephen J. Forman, Leslie Popplewell et al.|Biology of Blood and Marrow Transplantation|2010Cited by 522
Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell TransplantationAlex F. Herrera, Philippe Armand, Matthew Mei et al.|Journal of Clinical Oncology|2016Cited by 187
Polatuzumab Vedotin Combined with R-ICE (PolaR-ICE) As Second-Line Therapy in Relapsed/Refractory Diffuse Large B-Cell LymphomaAlex F. Herrera, Matthew J. Matasar, Lu Chen et al.|Blood|2022Cited by 18
138 | PHASE 2 ELARA TRIAL 4‐YEAR UPDATE: CLINICAL OUTCOMES OF TISAGENLECLEUCEL IN PATIENTS (PTS) WITH HIGH‐RISK RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL)Catherine Thiéblemont, Nathan Fowler, M. Dreyling et al.|Hematological Oncology|2025Cited by 1